Next Article in Journal
Telomere Maintenance in Pediatric Cancer
Previous Article in Journal
Suppression of 6-Hydroxydopamine-Induced Oxidative Stress by Hyperoside Via Activation of Nrf2/HO-1 Signaling in Dopaminergic Neurons
Open AccessArticle

Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer

1
Discipline of Surgery, Breast Cancer Research Unit, Basil Hetzel Institute, University of Adelaide, Adelaide, SA 5011, Australia
2
Department of Life Science Dentistry, The Nippon Dental University, Niigata 951-8580, Japan
3
Department of Oral and Maxillofacial Radiology, The Nippon Dental University School of Life Dentistry at Niigata, Niigata 951-8580, Japan
4
Faculty of Engineering, Niigata University, Niigata 950-2181, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(23), 5835; https://doi.org/10.3390/ijms20235835
Received: 10 October 2019 / Revised: 11 November 2019 / Accepted: 19 November 2019 / Published: 20 November 2019
(This article belongs to the Section Molecular Toxicology)
Near-infrared photoimmunotherapy (NIR-PIT) is a new and promising cancer therapy based on a monoclonal antibody conjugated to a photosensitizer which is activated by near-infrared light irradiation, causing cell death. We investigated NIR-PIT using a small protein mimetic (6–7 kDa), Affibody molecules, instead of a monoclonal antibody for HER2-overexpressing cancer. Because of its small size, the Affibody has rapid clearance, high imaging contrast, and good tumor penetration. Due to the small size of the Affibodies, which can cross the blood–brain barrier, NIR-PIT using Affibodies has the potential to extend the target cancer of NIR-PIT, including brain metastases. In vitro, NIR-PIT using HER2 Affibody–IR700Dye conjugates induced the selective destruction of HER2-overexpressing breast cancer cells without damage to control cells having low level expression of HER2. HER2-overexpressing cancer cells showed necrotic cell death and their viability maintained at low levels, even 5 days after NIR-PIT. In contrast, treatment with high concentration of HER2 Affibody–IR700Dye conjugate alone or irradiation with high dose of NIR light alone was without effect on cell viability. Affibody and IR700Dye are currently used clinically, and therefore, we would expect the current formulation to be safely and quickly transitioned into clinical trials. View Full-Text
Keywords: photoimmunotherapy; NIR-PIT; IR700Dye; Affibody; breast cancer; HER2 photoimmunotherapy; NIR-PIT; IR700Dye; Affibody; breast cancer; HER2
Show Figures

Graphical abstract

MDPI and ACS Style

Yamaguchi, H.; Pantarat, N.; Suzuki, T.; Evdokiou, A. Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer. Int. J. Mol. Sci. 2019, 20, 5835. https://doi.org/10.3390/ijms20235835

AMA Style

Yamaguchi H, Pantarat N, Suzuki T, Evdokiou A. Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer. International Journal of Molecular Sciences. 2019; 20(23):5835. https://doi.org/10.3390/ijms20235835

Chicago/Turabian Style

Yamaguchi, Haruka; Pantarat, Namfon; Suzuki, Takamasa; Evdokiou, Andreas. 2019. "Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer" Int. J. Mol. Sci. 20, no. 23: 5835. https://doi.org/10.3390/ijms20235835

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop